Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I

Arnab Roy Chowdhury, Shalini Sharma, Suparna Mandal, Anindya Goswami, Sibabrata Mukhopadhyay, Hemanta K. Majumder

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Luteolin, a naturally occurring flavonoid, is abundant in our daily dietary intake. It exhibits a wide spectrum of pharmacological properties, but little is known about its biochemical targets other than the fact that it induces topoisomerase II-mediated apoptosis. In the present study, we show that luteolin completely inhibits the catalytic activity of eukaryotic DNA topoisomerase I at a concentration of 40 μM, with an IC50 of 5 μM. Preincubation of enzyme with luteolin before adding a DNA substrate increases the inhibition of the catalytic activity (IC50 = 0.66 μM). Treatment of DNA with luteolin before addition of topoisomerase I reduces this inhibitory effect. Subsequent fluorescence tests show that luteolin not only interacts directly with the enzyme but also with the substrate DNA, and intercalates at a very high concentration (> 250 μM) without binding to the minor groove. Direct interaction between luteolin and DNA does not affect the assembly of the enzyme-DNA complex, as evident from the electrophoretic mobility-shift assays. Here we show that the inhibition of topoisomerase I by luteolin is due to the stabilization of topoisomerase-I DNA-cleavable complexes. Hence, luteolin is similar to camptothecin, a class I inhibitor, with respect to its ability to form the topoisomerase I-mediated 'cleavable complex'. But, unlike camptothecin, luteolin interacts with both free enzyme and substrate DNA. The inhibitory effect of luteolin is translated into concanavalin A-stimulated mouse splenocytes, with the compound inducing SDS-K+-precipitable DNA-topoisomerase complexes. This is the first report on luteolin as an inhibitor of the catalytic activity of topoisomerase I, and our results further support its therapeutic potential as a lead anti-cancer compound that poisons topoisomerases.

Original languageEnglish (US)
Pages (from-to)653-661
Number of pages9
JournalBiochemical Journal
Volume366
Issue number2
DOIs
StatePublished - Sep 1 2002
Externally publishedYes

Fingerprint

Luteolin
Type I DNA Topoisomerase
Poisons
Flavonoids
Neoplasms
DNA
Camptothecin
Catalyst activity
Enzymes
Inhibitory Concentration 50
Substrates
Electrophoretic mobility
Type II DNA Topoisomerase
Electrophoretic Mobility Shift Assay
Concanavalin A
Assays
Stabilization
Fluorescence

Keywords

  • Cleavable complex
  • DNA intercalator
  • Inhibitor
  • Topoisomerase poison

ASJC Scopus subject areas

  • Biochemistry
  • Medicine(all)
  • Molecular Biology
  • Cell Biology

Cite this

Chowdhury, A. R., Sharma, S., Mandal, S., Goswami, A., Mukhopadhyay, S., & Majumder, H. K. (2002). Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochemical Journal, 366(2), 653-661. https://doi.org/10.1042/BJ20020098

Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. / Chowdhury, Arnab Roy; Sharma, Shalini; Mandal, Suparna; Goswami, Anindya; Mukhopadhyay, Sibabrata; Majumder, Hemanta K.

In: Biochemical Journal, Vol. 366, No. 2, 01.09.2002, p. 653-661.

Research output: Contribution to journalArticle

Chowdhury, AR, Sharma, S, Mandal, S, Goswami, A, Mukhopadhyay, S & Majumder, HK 2002, 'Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I', Biochemical Journal, vol. 366, no. 2, pp. 653-661. https://doi.org/10.1042/BJ20020098
Chowdhury, Arnab Roy ; Sharma, Shalini ; Mandal, Suparna ; Goswami, Anindya ; Mukhopadhyay, Sibabrata ; Majumder, Hemanta K. / Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. In: Biochemical Journal. 2002 ; Vol. 366, No. 2. pp. 653-661.
@article{26b8eecca05f4aaeb71d9ad8e40ba138,
title = "Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I",
abstract = "Luteolin, a naturally occurring flavonoid, is abundant in our daily dietary intake. It exhibits a wide spectrum of pharmacological properties, but little is known about its biochemical targets other than the fact that it induces topoisomerase II-mediated apoptosis. In the present study, we show that luteolin completely inhibits the catalytic activity of eukaryotic DNA topoisomerase I at a concentration of 40 μM, with an IC50 of 5 μM. Preincubation of enzyme with luteolin before adding a DNA substrate increases the inhibition of the catalytic activity (IC50 = 0.66 μM). Treatment of DNA with luteolin before addition of topoisomerase I reduces this inhibitory effect. Subsequent fluorescence tests show that luteolin not only interacts directly with the enzyme but also with the substrate DNA, and intercalates at a very high concentration (> 250 μM) without binding to the minor groove. Direct interaction between luteolin and DNA does not affect the assembly of the enzyme-DNA complex, as evident from the electrophoretic mobility-shift assays. Here we show that the inhibition of topoisomerase I by luteolin is due to the stabilization of topoisomerase-I DNA-cleavable complexes. Hence, luteolin is similar to camptothecin, a class I inhibitor, with respect to its ability to form the topoisomerase I-mediated 'cleavable complex'. But, unlike camptothecin, luteolin interacts with both free enzyme and substrate DNA. The inhibitory effect of luteolin is translated into concanavalin A-stimulated mouse splenocytes, with the compound inducing SDS-K+-precipitable DNA-topoisomerase complexes. This is the first report on luteolin as an inhibitor of the catalytic activity of topoisomerase I, and our results further support its therapeutic potential as a lead anti-cancer compound that poisons topoisomerases.",
keywords = "Cleavable complex, DNA intercalator, Inhibitor, Topoisomerase poison",
author = "Chowdhury, {Arnab Roy} and Shalini Sharma and Suparna Mandal and Anindya Goswami and Sibabrata Mukhopadhyay and Majumder, {Hemanta K.}",
year = "2002",
month = "9",
day = "1",
doi = "10.1042/BJ20020098",
language = "English (US)",
volume = "366",
pages = "653--661",
journal = "Biochemical Journal",
issn = "0264-6021",
publisher = "Portland Press Ltd.",
number = "2",

}

TY - JOUR

T1 - Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I

AU - Chowdhury, Arnab Roy

AU - Sharma, Shalini

AU - Mandal, Suparna

AU - Goswami, Anindya

AU - Mukhopadhyay, Sibabrata

AU - Majumder, Hemanta K.

PY - 2002/9/1

Y1 - 2002/9/1

N2 - Luteolin, a naturally occurring flavonoid, is abundant in our daily dietary intake. It exhibits a wide spectrum of pharmacological properties, but little is known about its biochemical targets other than the fact that it induces topoisomerase II-mediated apoptosis. In the present study, we show that luteolin completely inhibits the catalytic activity of eukaryotic DNA topoisomerase I at a concentration of 40 μM, with an IC50 of 5 μM. Preincubation of enzyme with luteolin before adding a DNA substrate increases the inhibition of the catalytic activity (IC50 = 0.66 μM). Treatment of DNA with luteolin before addition of topoisomerase I reduces this inhibitory effect. Subsequent fluorescence tests show that luteolin not only interacts directly with the enzyme but also with the substrate DNA, and intercalates at a very high concentration (> 250 μM) without binding to the minor groove. Direct interaction between luteolin and DNA does not affect the assembly of the enzyme-DNA complex, as evident from the electrophoretic mobility-shift assays. Here we show that the inhibition of topoisomerase I by luteolin is due to the stabilization of topoisomerase-I DNA-cleavable complexes. Hence, luteolin is similar to camptothecin, a class I inhibitor, with respect to its ability to form the topoisomerase I-mediated 'cleavable complex'. But, unlike camptothecin, luteolin interacts with both free enzyme and substrate DNA. The inhibitory effect of luteolin is translated into concanavalin A-stimulated mouse splenocytes, with the compound inducing SDS-K+-precipitable DNA-topoisomerase complexes. This is the first report on luteolin as an inhibitor of the catalytic activity of topoisomerase I, and our results further support its therapeutic potential as a lead anti-cancer compound that poisons topoisomerases.

AB - Luteolin, a naturally occurring flavonoid, is abundant in our daily dietary intake. It exhibits a wide spectrum of pharmacological properties, but little is known about its biochemical targets other than the fact that it induces topoisomerase II-mediated apoptosis. In the present study, we show that luteolin completely inhibits the catalytic activity of eukaryotic DNA topoisomerase I at a concentration of 40 μM, with an IC50 of 5 μM. Preincubation of enzyme with luteolin before adding a DNA substrate increases the inhibition of the catalytic activity (IC50 = 0.66 μM). Treatment of DNA with luteolin before addition of topoisomerase I reduces this inhibitory effect. Subsequent fluorescence tests show that luteolin not only interacts directly with the enzyme but also with the substrate DNA, and intercalates at a very high concentration (> 250 μM) without binding to the minor groove. Direct interaction between luteolin and DNA does not affect the assembly of the enzyme-DNA complex, as evident from the electrophoretic mobility-shift assays. Here we show that the inhibition of topoisomerase I by luteolin is due to the stabilization of topoisomerase-I DNA-cleavable complexes. Hence, luteolin is similar to camptothecin, a class I inhibitor, with respect to its ability to form the topoisomerase I-mediated 'cleavable complex'. But, unlike camptothecin, luteolin interacts with both free enzyme and substrate DNA. The inhibitory effect of luteolin is translated into concanavalin A-stimulated mouse splenocytes, with the compound inducing SDS-K+-precipitable DNA-topoisomerase complexes. This is the first report on luteolin as an inhibitor of the catalytic activity of topoisomerase I, and our results further support its therapeutic potential as a lead anti-cancer compound that poisons topoisomerases.

KW - Cleavable complex

KW - DNA intercalator

KW - Inhibitor

KW - Topoisomerase poison

UR - http://www.scopus.com/inward/record.url?scp=0036711591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036711591&partnerID=8YFLogxK

U2 - 10.1042/BJ20020098

DO - 10.1042/BJ20020098

M3 - Article

VL - 366

SP - 653

EP - 661

JO - Biochemical Journal

JF - Biochemical Journal

SN - 0264-6021

IS - 2

ER -